Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240980504> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4240980504 endingPage "841" @default.
- W4240980504 startingPage "841" @default.
- W4240980504 abstract "Fabry disease (FD) is an ultra-rare genetic lysosomal storage disease caused by pathologic gene variants resulting in insufficient expression of α-galactosidase A. This enzyme deficiency leads to accumulation of globotriaosylceramide and globotriaosylsphingosine in plasma and in different cells throughout the body, causing major cardiovascular, renal, and nervous system complications. Until 2018, reimbursed enzyme replacement therapy (ERT) for FD was available in all European Union countries except Poland. We present the preliminary results of the first two years of reimbursed ERT in Poland. We obtained data from the seven largest academic centers in Katowice, Kraków, Wrocław, Poznań, Gdańsk, Warszawa, and Łódź. The questionnaire included the following data: number of patients treated, number of patients qualified for ERT, and patient characteristics. All centers returned completed questionnaires that included data for a total of 71 patients (28 men and 43 women) as of June 2021. Thirty-five patients with the diagnosis of FD confirmed by genetic testing (22 men and 13 women) had already qualified for reimbursed ERT. Mean (SD) age at the commencement of the ERT program was 39.6 (15.5) years (range 18-79 years). Mean time from the first clinical symptoms reported by the patients to the FD diagnosis was 21.1 (8.9) years, and the mean time from the final diagnosis of FD to the beginning of ERT was 4.7 (4.6) years. FD is still underdiagnosed in Poland. To identify undiagnosed FD patients and to ensure that patients in Poland benefit fully from ERT, implementation of an effective nationwide screening strategy and close cooperation with a network of rare disease centers is advised." @default.
- W4240980504 created "2022-05-12" @default.
- W4240980504 creator A5009010243 @default.
- W4240980504 creator A5010671677 @default.
- W4240980504 creator A5017637533 @default.
- W4240980504 creator A5021965872 @default.
- W4240980504 creator A5022932356 @default.
- W4240980504 creator A5029283766 @default.
- W4240980504 creator A5031939693 @default.
- W4240980504 creator A5038476377 @default.
- W4240980504 creator A5045007278 @default.
- W4240980504 creator A5056663230 @default.
- W4240980504 date "2021-08-20" @default.
- W4240980504 modified "2023-10-18" @default.
- W4240980504 title "First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland" @default.
- W4240980504 cites W2789753965 @default.
- W4240980504 cites W2808184073 @default.
- W4240980504 cites W2893863402 @default.
- W4240980504 cites W2995824843 @default.
- W4240980504 cites W3028150310 @default.
- W4240980504 cites W4211146209 @default.
- W4240980504 cites W4244103045 @default.
- W4240980504 cites W4287064009 @default.
- W4240980504 doi "https://doi.org/10.12688/f1000research.55313.1" @default.
- W4240980504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34745562" @default.
- W4240980504 hasPublicationYear "2021" @default.
- W4240980504 type Work @default.
- W4240980504 citedByCount "1" @default.
- W4240980504 countsByYear W42409805042023 @default.
- W4240980504 crossrefType "journal-article" @default.
- W4240980504 hasAuthorship W4240980504A5009010243 @default.
- W4240980504 hasAuthorship W4240980504A5010671677 @default.
- W4240980504 hasAuthorship W4240980504A5017637533 @default.
- W4240980504 hasAuthorship W4240980504A5021965872 @default.
- W4240980504 hasAuthorship W4240980504A5022932356 @default.
- W4240980504 hasAuthorship W4240980504A5029283766 @default.
- W4240980504 hasAuthorship W4240980504A5031939693 @default.
- W4240980504 hasAuthorship W4240980504A5038476377 @default.
- W4240980504 hasAuthorship W4240980504A5045007278 @default.
- W4240980504 hasAuthorship W4240980504A5056663230 @default.
- W4240980504 hasBestOaLocation W42409805041 @default.
- W4240980504 hasConcept C105639569 @default.
- W4240980504 hasConcept C126322002 @default.
- W4240980504 hasConcept C144133560 @default.
- W4240980504 hasConcept C187212893 @default.
- W4240980504 hasConcept C2777404818 @default.
- W4240980504 hasConcept C2777687718 @default.
- W4240980504 hasConcept C2779134260 @default.
- W4240980504 hasConcept C2779969927 @default.
- W4240980504 hasConcept C2910001868 @default.
- W4240980504 hasConcept C71924100 @default.
- W4240980504 hasConceptScore W4240980504C105639569 @default.
- W4240980504 hasConceptScore W4240980504C126322002 @default.
- W4240980504 hasConceptScore W4240980504C144133560 @default.
- W4240980504 hasConceptScore W4240980504C187212893 @default.
- W4240980504 hasConceptScore W4240980504C2777404818 @default.
- W4240980504 hasConceptScore W4240980504C2777687718 @default.
- W4240980504 hasConceptScore W4240980504C2779134260 @default.
- W4240980504 hasConceptScore W4240980504C2779969927 @default.
- W4240980504 hasConceptScore W4240980504C2910001868 @default.
- W4240980504 hasConceptScore W4240980504C71924100 @default.
- W4240980504 hasLocation W42409805041 @default.
- W4240980504 hasLocation W42409805042 @default.
- W4240980504 hasLocation W42409805043 @default.
- W4240980504 hasOpenAccess W4240980504 @default.
- W4240980504 hasPrimaryLocation W42409805041 @default.
- W4240980504 hasRelatedWork W2043385706 @default.
- W4240980504 hasRelatedWork W2045380837 @default.
- W4240980504 hasRelatedWork W2149584682 @default.
- W4240980504 hasRelatedWork W2164951759 @default.
- W4240980504 hasRelatedWork W2295780894 @default.
- W4240980504 hasRelatedWork W2302032650 @default.
- W4240980504 hasRelatedWork W2397505386 @default.
- W4240980504 hasRelatedWork W2957603538 @default.
- W4240980504 hasRelatedWork W3152508416 @default.
- W4240980504 hasRelatedWork W3204238661 @default.
- W4240980504 hasVolume "10" @default.
- W4240980504 isParatext "false" @default.
- W4240980504 isRetracted "false" @default.
- W4240980504 workType "article" @default.